Last reviewed · How we verify
LM-302 Injection
LM-302 Injection is a monoclonal antibody targeting a specific molecular target.
LM-302 Injection is a monoclonal antibody targeting a specific molecular target. Used for Treatment of metastatic non-small cell lung cancer.
At a glance
| Generic name | LM-302 Injection |
|---|---|
| Also known as | ClAUDIN 18.2-ADC |
| Sponsor | LaNova Medicines Zhejiang Co., Ltd. |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
LM-302 Injection works by binding to its target, thereby modulating its activity and exerting its therapeutic effect.
Approved indications
- Treatment of metastatic non-small cell lung cancer
Common side effects
- Injection site reaction
Key clinical trials
- LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. (PHASE3)
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. (PHASE3)
- Study of LM-302 in Patients With Advance Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LM-302 Injection CI brief — competitive landscape report
- LM-302 Injection updates RSS · CI watch RSS
- LaNova Medicines Zhejiang Co., Ltd. portfolio CI